Why Commercial Real Estate Company W.P. Carey Shares Are Down Today
W.P. Carey faces market reaction as Q4 FY23 earnings reveal a revenue increase to $412.4 million but a decline in AFFO per share to $1.19 due to spin-off impacts.
Barclays Bets Big on Green Transition, Reportedly Turns Up the Heat on Oil & Gas Lending
Barclays eyes notable adjustment in energy financing, ceasing direct funding for fresh oil and gas fields. Delve into the Transition Finance Framework and its effects on fossil fuel funding. In response to climate activism, Barclays establishes ambitious goals to curb fossil fuel lending by 2025, emphasizing the Transition Finance Framework's role in shaping energy finance.
Why Is Moderna Stock Trading Lower Today?
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.
Good News For Sleep Disorder Patients – Takeda’s Therapy Shows Promise In Mid-Stage Study
Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.
Why Is Automotive Supplier Magna Stock Falling Today?
Magna's Q4 2023 performance with $10.45 billion in sales, a 9% YoY increase. Dive into details on dividends, adjusted EBIT, and guidance for fiscal years 2024 and 2026.
Why HR & Payroll Provider Paylocity Shares Are Diving Today
Paylocity impresses with a 20% year-over-year surge in Q2 FY24 revenue, reaching $326.4 million and surpassing analyst forecasts. Paylocity's innovative AI-driven initiatives propel growth, with Co-CEO Steve Beauchamp highlighting a 16% increase in recurring revenue.
Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies
Tesla, relegated from seventh to ninth on the mega-cap leaderboard, can give way to other companies that are more 'magnificent.'
DNA Sequencing Kit Provider Illumina’s Q4 Earnings Edge Above Street Estimates, Works To Resolve GRAIL Quickly
Illumina exceeds Q4 2023 expectations with $1.12 billion sales, up 4% YoY. CEO Jacob Thaysen anticipates growth and outlines strategic priorities for 2024.
Continuous Glucose Monitor Maker Dexcom’s Q4 Profit Triples On Volume Growth And New Customer Additions
Dexcom's Q4 2023 performance, reporting $1.03 billion sales, $256.3 million profits, and beating estimates. Dexcom projects $4.15-$4.35 billion in 2024 revenues. William Blair affirms Outperform rating.
Motorola Shares Are Down Premarket Despite Earnings Beat: What’s Going On?
Motorola Solutions beats sales estimates in Q4 FY23, driven by robust growth in North America and International markets. Explore the company's strong performance and strategic initiatives. Motorola Solutions reports record backlog and expanded margins in Q4 FY23, accompanied by increased share repurchase authorization.